Fernando A. Bozza

TL;DR: A minimum set of common outcome measures for studies of COVID-19, which includes a measure of viral burden, patient survival, and patient progression through the health-care system by use of the WHO Clinical Progression Scale are urged.

TL;DR: In this article, the authors used a multiplex system for simultaneous detection of 17 cytokines (IL-1β, IL-2, IL 4, IL 5, IL 6, IL 7, IL 8, IL 9, IL 10, IL 11, IL 12, IL 13, interferon-γ, MCP-1, macrophage inflammatory protein-1 and tumour necrosis factor-α).

TL;DR: It is demonstrated that increased platelet activation and platelet-monocyte aggregate formation are observed in severe COVID-19 patients, but not in patients presenting mild CO VID-19 syndrome, and these data shed light on new pathological mechanisms involving plateletactivation and Platelet-dependent monocyte TF expression, which were associated with COVID -19 severity and mortality.

TL;DR: Protective effect of this heme-catabolizing enzyme relies on its ability to prevent tissue damage caused by the circulating free heme released from hemoglobin during infection, and it is proposed that targeting freeHeme by HPX might be used therapeutically to treat severe sepsis.

TL;DR: The use of a multiple cytokine assay platform was suitable for identifying distinct cytokine profiles associated with the dengue clinical manifestations and severity and MIP-β is indicated for the first time as a good prognostic marker in contrast to IFN-γ that was associated with disease severity.